ViiV Healthcare receives EU marketing authorisation for Dovato (dolutegravir/lamivudine), a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection

3 July 2019 - Authorisation based on GEMINI pivotal trials in which Dovato achieved non-inferior efficacy compared to a dolutegravir-based, three-drug ...

Read more →

Janssen submits marketing authorisation application for darunavir-based single tablet regimen for treatment of HIV-1 to European Medicines Agency

12 September 2016 - Janssen today announced the submission of a Marketing Authorisation Application to the EMA, seeking approval for ...

Read more →

European Commission grants marketing authorization for Gilead’s once-daily Truvada for reducing the risk of sexually acquired HIV-1

22 August 2016  - Truvada is the first anti-retroviral medicine to be licensed in Europe for pre-exposure prophylaxis, in combination with ...

Read more →

First medicine for HIV pre-exposure prophylaxis recommended for approval in the EU

22 July 2016 - Truvada to enhance existing HIV prevention strategies. ...

Read more →

EMA publishes EPAR for Odefsey (emtricitabine with rilpivirine hydrochloride and tenofovir alafenamide fumarate)

8 July 2016 - The EMA has published an EPAR for Gilead Sciences' Odefsey. ...

Read more →

European Commission grants marketing authorization for Gilead’s single tablet regimen Odefsey (emtricitabine, rilpivirine, tenofovir alafenamide) for the treatment of HIV

23 June 2016 - Odefsey is the second single tablet regimen containing the Descovy backbone and the third product in Gilead’s ...

Read more →

European Commission grants marketing authorization for Gilead’s fixed dose combination Descovy (emtricitabine with tenofovir alafenamide fumarate) for treatment of HIV

25 April 2016 - Gilead Sciences today announced that the European Commission has granted marketing authorization for two doses of Descovy ...

Read more →

European CHMP adopts positive opinion for Gilead’s fixed-dose combination Descovy (emtricitabine/tenofovir alafenamide) for the treatment of HIV

26 February 2016 - Gilead Sciences, Inc. today announced that the CHMP, the scientific committee of the EMA, has adopted a ...

Read more →